- GTx (NASDAQ:GTXI) has agreed to merge with privately held cancer therapy developer Oncternal Therapeutics in an all-stock deal.
- More news on: GTx, Inc., AbbVie Inc., Healthcare stocks news, Merger & acquisition news, Read more ...
Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
CORAL GABLES, FL / ACCESSWIRE / March 7, 2019 / The healthcare stock market has gotten off to an impressive start in the first few months of 2019, as companies in the healthcare sector work to pioneer innovative drug treatment options and care solutions for the millions of patients in need...
-- Merger will combine Oncternal’s clinical stage oncology pipeline and expertise with GTx’s preclinical Selective Androgen Receptor Degrader (SARD) program for castration-resistant prostate cancer -- -- Conference call to be held today at 8:30 a.m. Eastern Time/5:30 a.m....
NEW YORK, Feb. 07, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Skyworks Solutions, Inc. (NASDAQ:SWKS), Atmos Energy Corporation (NYSE:ATO), E...